{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:26:34Z","timestamp":1794327994365,"version":"4.9.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41409-020-01150-4","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T17:39:51Z","timestamp":1612201191000},"page":"1232-1234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and S\u00e9zary syndrome: never-late, never-never?"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chathuri","family":"Abeyakoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"1150_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703\u201314. https:\/\/doi.org\/10.1182\/blood-2018-11-881268","journal-title":"Blood"},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3109\/10428194.2012.729831","volume":"54","author":"MH Imam","year":"2013","unstructured":"Imam MH, Shenoy PJ, Flowers CR, Phillips A, Lechowicz MJ. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma. 2013;54:752\u20139. https:\/\/doi.org\/10.3109\/10428194.2012.729831","journal-title":"Leuk Lymphoma"},{"key":"1150_CR3","doi-asserted-by":"publisher","unstructured":"Photiou L, van der Weyden C, McCormack C, Miles Prince H. Systemic treatment options for advanced-stage mycosis fungoides and S\u00e9zary syndrome. Curr Oncol Rep. 2018. https:\/\/doi.org\/10.1007\/s11912-018-0678-x","DOI":"10.1007\/s11912-018-0678-x"},{"key":"1150_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz S, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390:555\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(17)31266-7","journal-title":"Lancet"},{"key":"1150_CR5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192\u2013204. https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6","journal-title":"Lancet Oncol"},{"key":"1150_CR6","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","volume":"28","author":"RF Duarte","year":"2010","unstructured":"Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010;28:4492\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.3241","journal-title":"J Clin Oncol."},{"key":"1150_CR7","doi-asserted-by":"publisher","unstructured":"Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;3347\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.57.5597","DOI":"10.1200\/JCO.2014.57.5597"},{"key":"1150_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/bmt.2014.161","volume":"49","author":"MJ Lechowicz","year":"2014","unstructured":"Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transpl. 2014;49:1360\u20135. https:\/\/doi.org\/10.1038\/bmt.2014.161","journal-title":"Bone Marrow Transpl"},{"key":"1150_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbmt.2019.08.019","volume":"26","author":"M Iqbal","year":"2020","unstructured":"Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, et al. Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2020;26:76\u201382. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.019","journal-title":"Biol Blood Marrow Transplant."},{"key":"1150_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00277-018-3275-z","volume":"97","author":"L Cudillo","year":"2018","unstructured":"Cudillo L, Cerretti R, Picardi A, Mariotti B, De Angelis G, Cantonetti M, et al. Allogeneic hematopoietic stem cell transplantation in primary cutaneous T cell lymphoma. Ann Hematol. 2018;97:1041\u20138. https:\/\/doi.org\/10.1007\/s00277-018-3275-z","journal-title":"Ann Hematol"},{"key":"1150_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3324\/haematol.2013.098145","volume":"99","author":"A de Masson","year":"2014","unstructured":"de Masson A, Beylot-Barry M, Bouaziz JD, de Latour RP, Aubin F, Garciaz S, et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French society of bone marrow transplantation and French study group on cutaneous lymphomas. Haematologica. 2014;99:527\u201334. https:\/\/doi.org\/10.3324\/haematol.2013.098145","journal-title":"Haematologica"},{"key":"1150_CR12","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","volume":"26","author":"C Hosing","year":"2015","unstructured":"Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26:2490\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdv473","journal-title":"Ann Oncol."},{"key":"1150_CR13","unstructured":"Onida F, Vall V, Saporiti G, Alberti-Violett S, Grifoni F, Goldaniga M, et al. Allogeneic hematopoietic stem cell transplantation as a curative treatment strategy for patients with advanced stage mycosis fungoides and Sezary syndrome: 2019 Update of the Milan Experience; World Congress of Cutanoeous Lymphoma: Barcelona. 2020."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01150-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01150-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01150-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T20:20:22Z","timestamp":1655238022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01150-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01150-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}